Arranged with the American Society of Microbiology (ASM)

Convenors: Achim Schwenk (London, UK); William Bishai (Baltimore, US)

• Laboratory diagnosis and drug susceptibility testing in tuberculosis
  Veronique Vincent (Geneva, CH)
• Epidemiology and infection control principles of XDR tuberculosis
  Shaheen Mehtar (Tygerberg, ZA)
• Pre-clinical testing of combination regimens for resistant TB infections
  William Bishai (Baltimore, US)
• Drug development and trials of new drugs for TB
  Clifton E. Barry (Rockville, US)

EW02: Pharmacokinetics and pharmacodynamics of anti-infective agents

Arranged with the International Society of Anti-Infective Pharmacology (ISAP)

Convenor: Johan W. Mouton (Nijmegen, NL)

• Introduction to PK/PD
  Hartmut Derendorf (Gainesville, US)
• PK/PD indices
  Johan W. Mouton (Nijmegen, NL)
• Protein binding/tissue distribution
  Ursula Theuretzbacher (Vienna, AT)
• Use of in vitro models to study emergence of resistance
  Inga Odenholt (Malmö, SE)
• From animal models to the patient
  William A. Craig (Madison, US)

EW03: Interpretive reading of the antibiogram: from MICs and inhibition zones to resistance mechanisms and clinical practice

Arranged with the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Convenors: Gunnar Kahlmeter (Vaxjo, SE); Roland Leclercq (Caen, FR)

• Concepts and needs for intrepretive reading of the antibiogram. The EUCAST perspective
  Derek Brown (Cambridge, UK)
• Enterobacteriaceae with beta-lactams
  Rafael Cantón (Madrid, ES)
• Non-fermentative Gram-negative bacilli
  David Livermore (London, UK)
• Enterobacteriaceae with aminoglycosides and fluoroquinolones
  Rafael Cantón (Madrid, ES)
• Staphylococci with beta-lactams, aminoglycosides, macrolides and glycopeptides
  Trevor Winstanley (Sheffield, UK)
• Streptococci and enterococci with beta-lactams, aminoglycosides,macrolides and glycopeptides
  Roland Leclercq (Caen, FR)
• Haemophilus spp. and Neisseria spp. with beta-lactams
  Trevor Winstanley (Sheffield, UK)
• Expert rules in expert systems. Are they just for experts?
  David Livermore (London, UK)

EW04: Management of patients with B and C viral hepatitis

Arranged with the ESCMID Study Group for Viral Hepatitis (ESGVH) and the European Association for the Study of the Liver (EASL)

Convenors: Dominique Salmon (Paris, FR); Andy Hoepelman (Amsterdam, NL)

• Virological tools for the optimal management of patients with chronic hepatitis (HCV, HBV)
  Charles Boucher (Amsterdam, NL)
• How to treat HCV mono-infected patients?
  Tarik Asselah (Paris, FR)
• How to treat HBV mono-infected patients?
  Dominique Salmon (Paris, FR)
• Management of HIV co-infected patients
  Andy Hoepelman (Amsterdam, NL)
• Clinical cases of HBV and HIV hepatitis coinfected patients
  Karine Lacombe (Paris, FR)
• Clinical case of HCV in an HIV co-infected patient
  Joop Arends (Utrecht, NL)

EW05: Diagnosis of parasitic infections

Arranged with the ESCMID Food- and Water-borne Infections Study Group (EFWISG) and the ESCMID Study Group for Clinical Parasitology (ESGCP)

Convenors: Birgitta Evengard (Stockholm, SE); Kevin Kerr (Harrogate, UK)

• Food-and waterborne parasitic infections in the immunocompromised patient: a practical approach to clinical diagnosis and management
  Nick Beeching (Liverpool, UK)
• Laboratory detection of food- and waterborne parasites in food, water and clinical specimens: will new techniques replace older methodologies?
  Jaco Verweij (Leiden, NL)
• Cyclospora – An emerging food-borne parasite
  Pablo Okhuysen (Houston, US)
• Malaria
  Tom van Gool (Amsterdam, NL)
• Cutaneous leishmaniasis
  Pierre Marty (Nice, FR)
• How far have multiplex-PCR and quality assessment of PCR come?
  Herve Pelloux (Grenoble, FR)
• Intestinal parasites
  Laetitia Kortbeek (Amsterdam, NL)

EW06: Clostridium difficile – future directions?

Arranged with the ESCMID Study Group for Clostridium difficile (ESGCD)

Convenors: Emilio Bouza (Madrid, ES); Mark Wilcox (Leeds, UK)

• Emerging CDAD among animals and possible transmission to humans?
  Maja Rupnik (Maribor, SI)
• Effective and non-effective infection control measures during outbreaks of CDAD
  Mark Wilcox (Leeds, UK)
• Recognition of community-acquired CDAD
  Ed Kuijper (Leiden, NL)
• Changing host susceptibility to C. difficile infections
  Ian Poxton (Edinburgh, UK)

EW07: Helicobacter pylori susceptibility testing and treatment failure

Arranged with the ESCMID Helicobacter Study Group (EHSG)

Convenor: Francis Mégraud (Bordeaux, FR)

• Why current treatments fail?
  Francis Mégraud (Bordeaux, FR)
• How to perform susceptibility testing?
  Alexander Hirschl (Vienna, AT)
• When to perform susceptibility testing?
  Leif Andersen (Copenhagen, DK)
• What will the management of H. pylori infection be in the future?
  Xavier Calvet (Barcelona, ES)

EW08: Animal models of biofilm infections

Arranged with the ESCMID Study Group for Biofilms (ESGB)

Convenor: Niels Hoiby (Copenhagen, DK)

• An overview of existing animal models of chronic biofilm growing bacterial lung infections with and without relationship to foreign bodies
  Niels Hoiby (Copenhagen, DK)
• An overview of animal models of foreign body-related peritonitis
  Claus Moser (Copenhagen, DK)
• Demonstration of the methods used to establish, evaluate, prevent and treat such biofilm infections including film clips showing 'how to do it'
  Thomas Bjarnsholt (Lyngby, DK)
• Prophylaxis and therapeutic aspects including use of antibiotics, quorum sensing inhibitors and immune modifiers
  Peter Ostrup Jensen (Copenhagen, DK)

EW09: New aspects in yeast infections

Arranged with the ESCMID Fungal Infection Study Group (EFISG)

Convenor: Manuel Cuenca-Estrella (Madrid, ES)

• Global epidemiology and patient at risk of invasive yeasts infections
  Cornelia Lass-Flörl (Innsbruck, AT)
• Current issues in the diagnosis of yeast infections
  Manuel Cuenca-Estrella (Madrid, ES)
• Treatment options in yeast infections
  Andrew Ullmann (Mainz, DE)
• Adjunctive therapies: adoptive immunotherapy in candidiasis
  Emmanuel Roilides (Thessaloniki, GR)